Kidney Research UK

The very simple key change that they've made, which on the face of it seems quite marginal, is that they've lowered the potassium threshold for starting Loquelma from six down to five point five.

That might sound like a small adjustment, but Kidney Research UK together with AstraZeneca both estimate it roughly doubles the number of patients in England and Wales who now qualify for potassium binders because there's a large group of people sitting there persistently in that five point five to six range who previously were just monitored and given dietary advice.

That-- and you're right, Andrew.

It looks like it's trivial, but actually, that's a really, really big shift in, in the people who we could use potassium binders in.